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Novelty and Impact: This is the first study to investigate the impact of tetracyclines and 
spironolactone use on gastro-oesophageal cancer risk. Our findings should provide considerable 
reassurance to the many GPs and patients prescribing or taking these medications. Previous 
evidence around the effect of bisphosphonates on gastro-oesophageal cancer risk is extremely 
mixed. Our work provides further evidence of no association, and could suggest that previous 
findings of positive associations might have been impaired by ascertainment bias. 
 
Abstract (Structured) 
Purpose: Bisphosphonate, tetracycline and spironolactone use has been shown to increase gastro-
oesophageal inflammation, an accepted risk factor for cancer. We explore whether use of these 
medications is associated with an increased risk of gastro-oesophageal cancer. 
 
Methods: A nested case-control study was conducted using the Primary Care Clinical Information 
Unit Research (PCCIUR) database from Scotland. Cases with oesophageal or gastric cancer between 
1999 and 2011 were matched to up to five controls based on age, gender, year of diagnosis and 
general practice. Medication use was ascertained using electronic prescribing records. Conditional 
logistic regression was used to calculate odds ratios (ORs) for the association between medication 
use and cancer risk after adjustment for comorbidities and other medication use.  
 
Results: A similar proportion of gastro-oesophageal cancer cases received bisphosphonates (3.9% vs. 
3.5%), tetracycline (6.0% vs. 6.0%) and spironolactone (1.4% vs. 1.1%) compared with the controls.  
The adjusted ORs for the association between gastro-oesophageal cancer and bisphosphonates, 
tetracycline and spironolactone were 1.05 (95% CI: 0.85, 1.31), 0.99 (95% CI: 0.84, 1.17) and 1.04 
(95% CI: 0.73, 1.49). Further analysis revealed bisphosphonates were associated with increased 
oesophageal cancer risk (1.34, 95% CI: 1.03, 1.74) but reduced gastric cancer risk (0.71, 95% CI: 0.49, 
1.03), although there was no obvious dose-response relationship. 
 
Conclusions: There is little evidence that that the use of bisphosphonate, tetracycline or 
spironolactone is associated with increased risk of gastro-oesophageal cancer. Our findings should 
reassure GPs and patients that these widely-used medications are safe with respect to gastro-
oesophageal cancer risk. 
Abstract (Unstructured) 
Bisphosphonate, tetracycline and spironolactone use has been shown to increase gastro-
oesophageal inflammation, an accepted risk factor for cancer. However, evidence on the effect of 
these medications on gastro-oesophageal cancer risk are mixed or missing entirely. Therefore, we 
conducted a nested case-control study using the Primary Care Clinical Information Unit Research 
(PCCIUR) database from Scotland. Cases with oesophageal or gastric cancer between 1999 and 2011 
were matched to up to five controls based on age, gender, year of diagnosis and general practice. 
Medication use was ascertained using electronic prescribing records. Conditional logistic regression 
was used to calculate odds ratios (ORs) for the association between medication use and cancer risk 
after adjustment for comorbidities and other medication use.  
 
A similar proportion of gastro-oesophageal cancer cases received bisphosphonates (3.9% vs. 3.5%), 
tetracycline (6.0% vs. 6.0%) and spironolactone (1.4% vs. 1.1%) compared with the controls.  The 
adjusted ORs for the association between gastro-oesophageal cancer and bisphosphonates, 
tetracycline and spironolactone were 1.05 (95% CI: 0.85, 1.31), 0.99 (95% CI: 0.84, 1.17) and 1.04 
(95% CI: 0.73, 1.49). Further analysis revealed bisphosphonates were associated with increased 
oesophageal cancer risk (1.34, 95% CI: 1.03, 1.74) but reduced gastric cancer risk (0.71, 95% CI: 0.49, 
1.03), although there was no obvious dose-response relationship. Overall, there is little evidence 
that that the use of bisphosphonate, tetracycline or spironolactone is associated with increased risk 
of gastro-oesophageal cancer. Our findings should reassure GPs and patients that these widely-used 
medications are safe with respect to gastro-oesophageal cancer risk. 
 
Introduction 
Oesophageal and gastric cancer are among the most common cancers in the world with around 
456,000 and 952,000 new cases diagnosed annually.1 Prognosis is extremely poor, even in OECD 
countries such as the UK, where around 55% of patients die within one year of diagnosis.2 Those 
who survive suffer marked reduction in their quality of life during treatment and recovery.3-5 
Inflammation is a well-established risk factor for cancer and various mechanisms have been 
proposed to explain this connection.6, 7 Several studies have demonstrated that patients with reflux 
oesophagitis have much higher oesophageal cancer risk8, most likely through the Barrett’s 
pathway.9, 10 It is also well recognised that chronic gastric inflammation, for example due to H. pylori 
infection, may progress to atrophy (e.g. ulceration), metaplasia, dysplasia, and gastric cancer.11, 12 
 
Bisphosphonates, tetracyclines and spironolactone are widely used medications with main 
indications of osteoporosis, infections/acne/rosacea and hypertension/cardiac failure, respectively. 
During 2015, approximately 8.2, 3.2 and 2.5 million were prescribed by English general 
practitioners.13 Long-term usage of these medications is common; for example the anti-fracture 
effects of some bisphosphonates are only realised after 36 months14 and tetracycline treatment for 
acne can last indefinitely.15  Each of these medications has been associated with increased risk of 
gastro-oesophageal inflammation.  Specifically, bisphosphonates have been shown in case reports to 
cause severe esophagitis including inflammation and thickening of the oesophageal wall16, 17 
Tetracyclines have also been shown to cause oesophagitis18, 19 with prospective studies finding an 
increased risk of oesophageal injury and ulceration20, and case reports demonstrating tetracycline 
induced lesions.21  Similarly, spironolactone has been associated with inflammation of the stomach 
including increased risk of gastric ulcers22, possibly due to impaired mucosal healing. 22, 23 Despite the 
widespread and prolonged use of these medications, epidemiological studies have focussed solely 
on bisphosphonates and gastro-oesophageal cancer risk24, and have yet to investigate the risk 
associated with tetracyclines and spironolactone use. 
 
Therefore, in a case-control study nested within a population-based primary care cohort from 
Scotland, we investigated whether bisphosphonates, tetracyclines or spironolactone were 
associated with an increased risk of gastro-oesophageal cancer. 
Methods 
Data 
We conducted a nested case-control study using the Primary Care Clinical Information Unit Research 
(PCCIUR) database.25 Between 1993 and 2011, the PCCIUR collected computerised medical records 
from approximately 15% of the Scottish general practice population, and includes details on patient 
demographics (e.g. age, deprivation), primary care encounters, clinical diagnoses and prescriptions. 
Access to the PCCIUR data was approved by the Research Applications and Data Management Team, 
University of Aberdeen. Ethical approval for this study was supplied by the Queen’s University 
Belfast, School of Medicine Ethics Committee (reference number: 15.43). 
Cases and controls 
Our primary outcome was gastro-oesophageal cancer since classifying tumours arising close to the 
oesophagogastric junction is difficult, and guidance on this process evolved throughout the study 
period.26, 27 However, separate site-specific estimates for oesophageal and gastric cancer were also 
presented. Cases were defined as patients with a first-time oesophageal (Read code: B10..) or gastric 
(Read code: B11..) cancer diagnosis after 1st January 1999 and before 30th April 2011. Up to five 
controls were randomly selected for each case matched on age, gender, year of diagnosis and 
general practice. The index date was defined as the diagnosis date of the case in each matched 
group.  The start of the exposure period was the latest of 1st January 1996 (as prescriptions before 
this were less likely to be generated electronically) or the date of general practice registration.  
Additionally, the exposure period was truncated to ensure it was identical across the matched 
groups.28 Cases and controls with an earlier cancer diagnosis (other than non-melanoma skin 
cancer), and those with less than three years of exposure prior to index date, were excluded from 
the matching process. 
Definition of exposure 
We identified prescriptions of bisphosphonates, tetracyclines and spironolactone from electronic 
prescription records. We used the British National Formulary (August 2016 version) to compile a list 
of proprietary and generic drug names containing these compounds (Appendix 1). We excluded 
prescriptions before 1st January 1996 and those in the year prior to the index date (to prevent 
reverse causation). We defined patients as users if they had at least one prescription during the 
exposure period. To enable the testing of dose-response relationships we calculated the total 
number of prescriptions received during the exposure period and split patients into lower (less than 
the median) and higher (more than the median) users. We conducted a separate analysis for 
nitrogen-containing bisphosphonates, as these have a mechanism of action distinct from non-
nitrogen containing products29, and alendronate, which has been previously linked to cases of 
esophageal cancer.30 
Confounding factors 
We identified eleven comorbidities (myocardial infarction, heart failure, peripheral vascular disease, 
cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary 
disease, rheumatoid arthritis, diabetes, renal disease, liver disease) using Read codes recorded by 
the GP during the exposure period.31 Use of aspirin and statins within the exposure period were 
identified from prescription records (Appendix 1) as associations with oesophageal and/or gastric 
cancer have been identified previously.32, 33 Lifestyle data including obesity (BMI>30), smoking status 
(never, ex, current) and alcohol use (none, low [e.g. moderate or light drinker], high [e.g. above 
recommended limits, chronic alcoholism]) were also recorded in the PCCIUR data using Read codes.  
Statistical Analysis 
We calculated descriptive statistics and compared the demographics and clinical characteristics of 
the cases and controls. We used conditional logistic regression to estimate odds ratios (ORs) with 
95% confidence intervals (CIs) for the association between medication use and gastro-oesophageal 
cancer.  The matched design of the study accounted for the effect of age, gender, general practice 
and year of diagnosis with additional adjustments were made for statin use (yes/no), aspirin use 
(yes/no) and the presence of each comorbidity (yes/no) using regression.  
 
We performed additional sensitivity analysis to investigate the impact of additionally adjusting for 
smoking, alcohol consumption and obesity using complete case and multiple imputation with 
chained equations (MICE) methods. The imputation used ordered logit models with age, gender and 
deprivation, separately for cases and controls. Briefly, MICE is a simulation-based approach for 
handling missing data which leads to valid statistical inferences.34 Sensitivity analyses were also 
conducted investigating the impact of excluding prescriptions in the two years prior to the index 
date (as opposed to one in the main analysis) and defining medication users as patients with at least 
three prescriptions (as opposed to one in the main analysis). Analyses was conducted using Stata 
version 13.35 
Results 
We identified 3,098 cases of gastro-oesophageal cancer (1,979 oesophageal and 1,119 gastric 
cancer) (Table 1). An average of 4.8 controls existed for each case with a median exposure period of 
5.5 years (min 3.0, max 15.1). There were some potentially important differences between cases and 
controls. Most notably, a larger proportion of cases had a history of COPD (11.7% vs 8.5%), and were 
more likely to be current or ex-smokers (64.7% vs 55.3%), drink high levels of alcohol (7.5% vs. 5.3%) 
and have a BMI under thirty (85.8% vs 79.9%). The proportion of missing data for smoking status and 
alcohol consumption was 21.5% and 32.0% respectively.  
 
Overall, 3.9% (122/3098) of cases and 3.5% (526/14937) of controls used bisphosphonates 
suggesting little association between bisphosphonate use and gastro-oesophageal cancer risk (ORadj= 
1.05; 95% CI: 0.85, 1.31) (Table 2).  There was evidence of a 34% increased risk (ORadj= 1.34; 95% CI: 
1.03, 1.74) of oesophageal cancer in bisphosphonate users but a reduction of 29% (ORadj= 0.71; 95% 
CI: 0.49, 1.03) in gastric cancer.  The association between bisphosphonate use and oesophageal or 
gastric cancer did not appear to follow a dose-response relationship. 
 
Tetracycline was used by 6.0% (186/3098) of cases and 6.0% (894/14937) of controls; there was no 
evidence of association with gastro-oesophageal cancer risk (ORadj= 0.99; 95% CI: 0.84, 1.17). 
Similarly, little associations were observed between tetracycline use and oesophageal (ORadj= 1.01; 
95% CI: 0.82, 1.25) and gastric cancer (ORadj= 0.96; 95% CI: 0.73, 1.28).  
 
Overall, 1.4% (43/3098) of cases and 1.1% (159/14937) of controls used spironolactone but there 
were small associations with gastro-oesophageal cancer risk after adjustment for confounders 
(ORadj= 1.04; 95%: 0.73, 1.49). Again, there was little evidence of higher risk for oesophageal or 
gastric cancer alone, with adjusted odds ratios of 1.04 (95% CI: 0.68, 1.61) and 1.05 (95% CI: 0.55, 
2.00) respectively. 
 
In general, our conclusions were little altered in sensitivity analyses (Table 3).  Similar associations 
were observed when excluding prescriptions in the two years prior to diagnosis rather than one (to 
reduce the risk of reverse causality), and when the exposure definition of ‘ever use’ was based upon 
three or more prescriptions rather than one. Additionally adjusting for lifestyle factors (smoking, 
alcohol consumption, and obesity), either in a complete case analysis or when using MICE, resulted 
in similar estimates to the main analysis. We also found slightly larger, although still moderate, 
associations when restricting our analysis to nitrogen-containing bisphosphonates (ORadj= 1.15; 95% 
CI: 0.90, 1.46), or alendronate alone (ORadj= 1.13; 95% CI: 0.87, 1.46), compared to the main analysis 
which combined all bisphosphonates. 
 Discussion 
In this study of oesophageal and gastric cancer cases and controls in a community-based population, 
we found little evidence of an association between gastro-oesophageal cancer risk and the use of 
bisphosphonates, tetracyclines or spironolactone. Although there was some evidence that 
bisphosphonates increased the risk of oesophageal cancer, there was no obvious dose-response 
relationship and these increases were largely offset by a reduction in gastric cancer risk. 
Strengths and limitations 
The main strength of our study lies in the high-quality and nationally representative data on which it 
is based.36  It is the first study to investigate the effect of tetracycline and spironolactone on gastro-
oesophageal cancer risk and has found no evidence of an increased incidence, which is important 
and reassuring given the large numbers of patients who use these medications often for prolonged 
periods of time. We used prescribing data collected as part of routine clinical care, in many cases, 
several years before the onset of oesophageal or gastric cancer which accurately reflects GP 
prescribing practices and negates the risk of recall bias.  Although a weakness of this approach is that 
we do not know if patients used their prescribed medications, the main conclusions were similar 
when restricting our analysis to patients who received multiple repeat prescriptions  (>12) where 
non-compliance is likely to be less of an issue. Additionally, GP records do not contain data on over-
the-counter medications which may have impaired our ability to accurately adjust for aspirin use 
(due to exposure misclassification). 
 
Our study is observational and hence open to confounding; although we have controlled for several 
of the key determinants of cancer risk through the matched design and analysis (e.g. age, 
comorbidities and general practice) some other risk factors, including ethnicity and nutrition, were 
not available. This could be a particular concern in the bisphosphonate analysis, as patients with 
osteoporosis may be more likely to report upper gastrointestinal disorders, even prior to 
bisphosphonate initiation.37 Our analysis is based on GP diagnosed cancer.  Although a recent CPRD 
study found that over 95% of gastro-oesophageal cancers are captured within GP records38, a higher 
proportion of oesophageal cancers were recorded in the Scottish Cancer Registry39 than the PCCIUR 
data, which could suggest some misclassification of cancer site in our study. This potential issue 
would not affect our primary analysis which combined oesophageal and gastric cancers. Finally, 
histological data were not available to allow a separate analysis of squamous cell carcinoma and 
adenocarcinoma, the two most common forms of oesophageal cancer. 
 Comparisons with other research 
To our knowledge, this is the first study to investigate the impact of tetracyclines and spironolactone 
use on gastro-oesophageal cancer risk.  
 
Several studies have previously examined the effect of bisphosphonates on gastro-oesophageal 
cancer risk. In agreement with our findings, two UK-based studies which combined the oesophageal 
and gastric cancer sites together in a single analysis found no significant association40, 41 with 
bisphosphonate use, while another Danish study reported a 37% decrease in risk.42 Although a 
recent meta-analysis reported no significant association between bisphosphonate use and 
oesophageal cancer risk24, several individual studies have observed an association. For example, one 
UK-based study reported a 30% increased risk of oesophageal cancer among bisphosphonate users, 
which was similar to the 34% effect size estimated in our study.43, 44 Our finding of reduced gastric 
cancer incidence among bisphosphonate users was replicated by several other studies43-45, including 
one which found a 39% reduction in the risk of gastric cancer42, although a recent meta-analysis 
reported no overall effect.24 Several studies investigating the effect of bisphosphonate use on cancer 
incidence, separately for both the oesophageal and gastric sites, reported a similar pattern to our 
study (i.e. increased risk of oesophageal cancer which was largely offset by a decreased risk of 
gastric cancer).43-45 
 
Implications 
Bisphosphonate, tetracycline and spironolactone are widely used and effective treatments for a 
range of indications including osteoporosis, infections/acne/rosacea and hypertension/cardiac 
failure respectively. Our study suggests that any inflammation caused by these medications does not 
substantially increase the risk of gastro-oesophageal cancer, and GPs or patients should not be 
unduly concerned about cancer risk when prescribing or taking these treatments. 
 
It is unclear why bisphosphonate users had an increased risk of oesophageal cancer in our study. 
Firstly, these results could represent a true causal association; bisphosphonates are well known to 
cause dyspepsia and other inflammatory changes (e.g. oesophagitis, mucosal abnormalities)46 which 
could form an important part of the upper-gastrointestinal cancer pathway.30 Perhaps more likely, 
particularly given our concurrent finding of lower gastric cancer risk among bisphosphonate users, is 
that these associations are at least partly driven by a form of ascertainment bias. One Danish study 
reported that, due to higher rates of gastrointestinal side effects, patients receiving bisphosphonates 
were more than twice as likely to undergo upper endoscopy (4.1% vs. 1.7%).42 This could lead to 
earlier detection of oesophageal cancer and more accurate classification of some oesophageal 
tumours proximal to the oesophagogastric junction in bisphosphonate users, which would have 
otherwise been incorrectly recorded as gastric in origin.42 
Conclusions 
Overall, our study provided little evidence that the use of bisphosphonate, tetracyclines or 
spironolactone are associated with increased risk of gastro-oesophageal cancer.  These findings 
should reassure GPs and patients that these widely-used medications are safe with respect to 
gastro-oesophageal cancer risk.  
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Tables and Figures 
Table 1: Characteristics of controls and cases with oesophageal or gastric cancer 
 Cases Controls 
Count 3,098 14,937 
Median Exposure Years (Min, Max) 5.5 (3.0, 15.1) 5.5 (3.0, 15.1) 
Year of Diagnosis   
1999-2003 1,063 (34.3%) 5,151 (34.5%) 
2004-2007 1,404 (45.3%) 6,741 (45.1%) 
2008-2011 631 (20.4%) 3,045 (20.4%) 
Mean Age (SD) 69.6 (11.3) 69.1 (11.2) 
0-39 26 (0.8%) 133 (0.9%) 
40-59 563 (18.2%) 2,807 (18.8%) 
60-79 1,886 (60.9%) 9,269 (62.1%) 
80+ 623 (20.1%) 2,728 (18.3%) 
Sex   
Female 1,095 (35.3%) 5,287 (35.4%) 
Male 2,003 (64.7%) 9,650 (64.6%) 
Smoking status   
Non-smoker 931 (35.3%) 5,147 (44.7%) 
Ex-smoker 898 (34.0%) 3,656 (31.8%) 
Current smoker 811 (30.7%) 2,708 (23.5%) 
Missing 458 3,426 
Alcohol Consumption   
No 551 (24.4%) 2,338 (23.3%) 
Low 1,534 (68.1%) 7,145 (71.3%) 
High 169 (7.5%) 532 (5.3%) 
Missing 844 4,922 
Obesity   
Not Obese 2,658 (85.8%) 11,932 (79.9%) 
Obese 440 (14.2%) 3,005 (20.1%) 
Deprivation Quintile   
1 (Least Deprived) 375 (12.3%) 1,776 (12.0%) 
2 555 (18.1%) 2,657 (18.0%) 
3 648 (21.2%) 3,137 (21.3%) 
4 748 (24.4%) 3,637 (24.6%) 
5 (Most Deprived) 734 (24.0%) 3,549 (24.1%) 
Missing 38 181 
Common Comorbiditiesa   
Connective Tissue Disease 1,377 (44.4%) 6,752 (45.2%) 
Diabetes 328 (10.6%) 1,422 (9.5%) 
COPD 361 (11.7%) 1,267 (8.5%) 
CVD 283 (9.1%) 1,214 (8.1%) 
MI 272 (8.8%) 1,181 (7.9%) 
Other Drug Use   
Aspirin 915 (29.5%) 4,217 (28.2%) 
Statin 753 (24.3%) 3,367 (22.5%) 
   
                                                          
a For brevity only the 5 most common comorbidities are listed. The full analysis included myocardial infarction 
(MI), heart failure, peripheral vascular disease, cerebrovascular disease (CVD), connective tissue disease, 
dementia, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, diabetes, renal disease and 
liver disease 
Table 2: Combined analysis of drug use risk with oesophageal and gastric cancer risk 
 
Cases Controls 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI)b 
Gastro-oesophageal combined 
Bisphosphonates     
Never 2,976 (96.1%) 14,411 (96.5%) Ref Ref 
Ever 122 (3.9%) 526 (3.5%) 1.09 (0.88,1.34) 1.05 (0.85,1.31) 
Lower Usage (1-18 prescriptions) 64 (2.1%) 249 (1.7%) 1.22 (0.92,1.61) 1.16 (0.87,1.55) 
Higher Usage (19+) 58 (1.9%) 277 (1.9%) 0.97 (0.72,1.31) 0.95 (0.71,1.29) 
Tetracycline     
Never 2,912 (94.0%) 14,043 (94.0%) Ref Ref 
Ever 186 (6.0%) 894 (6.0%) 1.01 (0.86,1.20) 0.99 (0.84,1.17) 
Lower Usage (1) 104 (3.4%) 542 (3.6%) 0.93 (0.75,1.16) 0.92 (0.74,1.14) 
Higher Usage (2+) 82 (2.6%) 352 (2.4%) 1.14 (0.89,1.45) 1.10 (0.86,1.42) 
Spironolactone     
Never 3,055 (98.6%) 14,778 (98.9%) Ref Ref 
Ever 43 (1.4%) 159 (1.1%) 1.24 (0.88,1.75) 1.04 (0.73,1.49) 
Lower Usage (1-10) 21 (0.7%) 77 (0.5%) 1.26 (0.77,2.05) 1.10 (0.67,1.81) 
Higher Usage (11+) 22 (0.7%) 82 (0.5%) 1.23 (0.76,1.98) 0.99 (0.60,1.62) 
Oesophageal 
Bisphosphonates     
Never 1,895 (95.8%) 9,254 (97.0%) Ref Ref 
Ever 84 (4.2%) 289 (3.0%) 1.40 (1.08,1.81) 1.34 (1.03,1.74) 
Lower Usage (1-18) 47 (2.4%) 127 (1.3%) 1.78 (1.25,2.51) 1.70 (1.20,2.43) 
Higher Usage (19+) 37 (1.9%) 162 (1.7%) 1.09 (0.75,1.58) 1.04 (0.71,1.52) 
Tetracycline     
Never 1,858 (93.9%) 8,976 (94.1%) Ref Ref 
Ever 121 (6.1%) 567 (5.9%) 1.04 (0.85,1.29) 1.01 (0.82,1.25) 
Lower Usage (1) 66 (3.3%) 341 (3.6%) 0.95 (0.72,1.24) 0.93 (0.70,1.22) 
Higher Usage (2+) 55 (2.8%) 226 (2.4%) 1.19 (0.88,1.61) 1.14 (0.83,1.55) 
Spironolactone     
Never 1,949 (98.5%) 9,436 (98.9%) Ref Ref 
Ever 30 (1.5%) 107 (1.1%) 1.27 (0.84,1.92) 1.04 (0.68,1.61) 
Lower Usage (1-10) 13 (0.7%) 55 (0.6%) 1.05 (0.57,1.95) 0.94 (0.50,1.75) 
Higher Usage (11+) 17 (0.9%) 52 (0.5%) 1.50 (0.86,2.61) 1.15 (0.64,2.06) 
Gastric 
Bisphosphonates     
Never 1,081 (96.6%) 5,157 (95.6%) Ref Ref 
Ever 38 (3.4%) 237 (4.4%) 0.72 (0.50,1.04) 0.71 (0.49,1.03) 
Lower Usage (1-18) 17 (1.5%) 122 (2.3%) 0.65 (0.39,1.08) 0.62 (0.37,1.04) 
Higher Usage (19+) 21 (1.9%) 115 (2.1%) 0.80 (0.49,1.29) 0.80 (0.49,1.31) 
Tetracycline     
Never 1,054 (94.2%) 5,067 (93.9%) Ref Ref 
Ever 65 (5.8%) 327 (6.1%) 0.96 (0.72,1.27) 0.96 (0.73,1.28) 
Lower Usage (1) 38 (3.4%) 201 (3.7%) 0.90 (0.63,1.29) 0.92 (0.64,1.31) 
Higher Usage (2+) 27 (2.4%) 126 (2.3%) 1.04 (0.68,1.59) 1.04 (0.68,1.59) 
Spironolactone     
Never 1,106 (98.8%) 5,342 (99.0%) Ref Ref 
Ever 13 (1.2%) 52 (1.0%) 1.18 (0.63,2.21) 1.05 (0.55,2.00) 
Lower Usage (1-10) 8 (0.7%) 22 (0.4%) 1.78 (0.78,4.08) 1.53 (0.66,3.57) 
Higher Usage (11+) 5 (0.4%) 30 (0.6%) 0.75 (0.29,1.98) 0.71 (0.27,1.87) 
 
                                                          
b Adjusted for statin and aspirin use, and the presence of myocardial infarction, heart failure, peripheral 
vascular disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary 
disease, rheumatoid arthritis, diabetes, renal disease and liver disease. Additionally conditioned on age, 
general practice and year of diagnosis 
Table 3: Sensitivity analysis 
 
Cases Controls 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI)c 
Bisphosphonates 
2- year exposure lag     
Never 3,001 (96.9%) 14,520 (97.2%) Ref Ref 
Ever 97 (3.1%) 417 (2.8%) 1.09 (0.86,1.37) 1.04 (0.82,1.33) 
Ever use ≥3 prescriptions     
Never 2,988 (96.4%) 14,442 (96.7%) Ref Ref 
Ever 110 (3.6%) 495 (3.3%) 1.05 (0.84,1.30) 1.01 (0.81,1.26) 
MId lifestyle adjusted     
Never 2,976 (96.1%) 14,411 (96.5%) Ref Ref 
Ever 122 (3.9%) 526 (3.5%) 1.09 (0.88,1.34) 1.03 (0.83,1.28) 
Lifestyle complete case     
Never 2,123 (96.0%) 9,218 (96.2%) Ref Ref 
Ever 88 (4.0%) 369 (3.8%) 1.00 (0.77,1.29) 0.93 (0.71,1.21) 
Nitrogen containing bisphosphonates  
Never 3,001 (96.9%) 14,551 (97.4%) Ref Ref 
Ever 97 (3.1%) 386 (2.6%) 1.18 (0.93,1.50) 1.15 (0.90,1.46) 
Alendronate only     
Never 3,015 (97.3%) 14,603 (97.8%) Ref Ref 
Ever 83 (2.7%) 334 (2.2%) 1.17 (0.91,1.51) 1.13 (0.87,1.46) 
Tetracycline 
2- year exposure lag     
Never 2,933 (94.7%) 14,200 (95.1%) Ref Ref 
Ever 165 (5.3%) 737 (4.9%) 1.10 (0.92,1.31) 1.07 (0.89,1.28) 
Ever use ≥3 prescriptions     
Never 3,049 (98.4%) 14,718 (98.5%) Ref Ref 
Ever 49 (1.6%) 219 (1.5%) 1.10 (0.80,1.50) 1.05 (0.76,1.45) 
MI lifestyle adjusted     
Never 2,912 (94.0%) 14,043 (94.0%) Ref Ref 
Ever 186 (6.0%) 894 (6.0%) 1.01 (0.86,1.20) 1.02 (0.86,1.20) 
Lifestyle complete case     
Never 2,067 (93.5%) 8,914 (93.0%) Ref Ref 
Ever 144 (6.5%) 673 (7.0%) 0.93 (0.76,1.13) 0.92 (0.75,1.13) 
Spironolactone 
2- year exposure lag     
Never 3,069 (99.1%) 14,805 (99.1%) Ref Ref 
Ever 29 (0.9%) 132 (0.9%) 1.02 (0.68,1.53) 0.82 (0.54,1.26) 
Ever use ≥3 prescriptions     
Never 3,061 (98.8%) 14,802 (99.1%) Ref Ref 
Ever 37 (1.2%) 135 (0.9%) 1.26 (0.87,1.83) 1.05 (0.72,1.54) 
MI lifestyle adjusted     
Never 3,055 (98.6%) 14,778 (98.9%) Ref Ref 
Ever 43 (1.4%) 159 (1.1%) 1.24 (0.88,1.75) 1.09 (0.76,1.57) 
Lifestyle complete case     
Never 2,175 (98.4%) 9,478 (98.9%) Ref Ref 
Ever 36 (1.6%) 109 (1.1%) 1.25 (0.83,1.89) 1.10 (0.72,1.69) 
                                                          
c Adjusted for statin and aspirin use, and the presence of myocardial infarction, heart failure, peripheral 
vascular disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary 
disease, rheumatoid arthritis, diabetes, renal disease and liver disease. Additionally conditioned on age, 
general practice and year of diagnosis 
d Multiple imputation with chained equations for smoking, alcohol consumption and obesity with age, gender 
and deprivation used in the imputation, separately for cases and controls, using chained ordered logit models 
Appendices 
Appendix 1: List of generic and proprietary drug names for each exposure and confounder 
medication 
Substance Name Drug Name 
Aspirin Asasantin, Aspirin, Caprin, Co-codaprin, Micropirin, Migramax, Nu-Seals 
Bisphosphonates Aclasta, Actonel, Alendronic acid, Aredia, Binosto, Bondronat, Bonefos, 
Bonviva, Clasteon, Clodronate, Didronel, Didronel PMO, Fosamax, Fosavance, 
Iasibon, Ibrandronic acid, Loron, Pamidronate, Risedronate, Zoledronic acid, 
Zometa 
Spironolactone Aldactide, Aldactone, Co-flumactone, Lasilactone, Spironolactone 
Statin Atorvastatin, Cholib, Crestor, Dorisin, Fluvastatin, Inegy, Lescol, Lipitor, 
Lipostat, Luvinsta, Pinmactil, Pravastatin, Rosuvastatin, Simvador, 
Simvastatin, Stefluvin, Zocor 
Tetracycline Acnamino, Aknemin, Democlocyline, Doxycycline, Doxylar, Efracea, 
Lymecycline, Minocin, Minocycline, Oxymycin, Oxytetracycline, Sebomin, 
Tetracycline, Tetralysal, Tigecycline, Tygacil, Vibramycin-D 
 
 
 
